$7.68
+2.7%Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโmonitor closely.
Capital-intensive growth: Heavy reinvestment limits current cash available but may drive future returns. Assess whether CapEx supports compelling growth opportunities with adequate ROI.
ATEC โข NASDAQ
| Alphatec Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-143.4M | -162.1M | -186.6M | -151.3M | -143M | -143M | -79M | -57M | -29M | -2.3M | -29.9M | -178.7M | -12.9M | -82.2M | -15.5M | -22.2M | -14.4M | -13.3M | -29.3M | -20.2M | |
105.1M | 83.3M | 59.7M | 43.9M | 30.2M | 30.2M | 11.6M | 8.5M | 6.8M | 7.5M | 12.4M | 19M | 18.4M | 26.3M | 23.8M | 19.9M | 17.2M | 12M | 8.7M | 10.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9K | -438K | -1.4M | -36K | 10K | -333K | 251K | 816K | -3.4M | -4.3M | -1.9M | 141K | 401K | 32K | |
73.7M | 73.3M | 81.2M | 40.6M | 36.5M | 36.5M | 17.7M | 11M | 5.3M | 3.9M | 1.6M | 2.6M | 4.6M | 4.1M | 3.7M | 2.4M | 3.2M | 3.6M | 2.9M | 314K | |
29.9M | 28.1M | 21.4M | 15.6M | 28.1M | 28.1M | 19.2M | 13.2M | 2.4M | -7.5M | 8.5M | 168.3M | 12.8M | 13.9M | 10.9M | 15.8M | 5.9M | 5.6M | 4.4M | 3.2M | |
(0.0) | (275K) | (333K) | (272K) | (223K) | (223K) | (190K) | (161K) | (134K) | (107K) | (920K) | (621K) | (565K) | (1.8M) | (989K) | (523K) | (426K) | (0.0) | (501K) | (93K) | |
-20.1M | -67.3M | -54.2M | -23.9M | -25.1M | -25.1M | -16M | -8.4M | -9.7M | -10.3M | -2.5M | -882K | -43.4M | 45M | -7.9M | 1.8M | -24.8M | -13.5M | -6.7M | -7.2M | |
45.2M | -44.7M | -78.5M | -75.1M | -73.3M | -73.3M | -46.4M | -33.1M | -25.6M | -8.7M | -10M | 10.1M | -20.3M | 7.8M | 11.6M | 13.4M | -14.8M | -5.5M | -19.5M | -13.2M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-42.5M | -93.1M | -80.5M | -49.5M | -68.5M | -68.5M | -23.1M | -13M | -6.9M | -7.6M | -9.1M | -12.2M | -11.3M | -15.1M | -17.4M | -8.9M | -16.3M | -13.2M | -13.4M | -8M | |
(0.0) | (0.0) | -55M | (0.0) | -83.2M | -83.2M | (0.0) | (0.0) | -15.1M | (1.1M) | (69.8M) | (0.0) | (0.0) | -4M | -2M | -620K | (1.9M) | (0.0) | (0.0) | (258K) | |
(0.0) | (0.0) | (0.0) | (0.0) | -6M | -6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 383K | 0.0 | 3.8M | |
-11M | 0.0 | -6.5M | -8.8M | 0.0 | 0.0 | -728K | 0.0 | 348K | 1.1M | 1.3M | 0.0 | 300K | -750K | -3.8M | 0.0 | -382K | 60K | 4.3M | -3.8M | |
-53.4M | -93.1M | -142M | -58.3M | -157.8M | -157.8M | -23.9M | -13M | -21.7M | -6.5M | (62M) | -12.2M | -11M | -19.1M | -19.4M | -9.5M | -14.4M | -12.7M | -9.1M | -8.9M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
0.0 | -560K | 212.1M | 0.0 | 100.9M | 100.9M | 111M | 55.8M | 51.9M | 24.4M | 114K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49.7M | 9.9M | -48K | 33.4M | |
74.8M | 58.8M | 149.7M | 35M | 271.3M | 271.3M | 19.8M | 8.4M | 2M | -6.6M | -43.5M | -6.9M | 30.7M | 10.7M | 8.4M | -7M | -6.3M | 324K | 21.4M | -3M | |
(0.0) | (0.0) | (0.0) | (0.0) | -31M | -31M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -48K | (0.0) | |
-44.8M | -2M | -4.9M | -3.8M | -60.1M | -60.1M | -58K | 0.0 | 51.9M | 24.4M | -114K | 0.0 | 0.0 | 8K | 76K | 104K | -267K | 38K | 70K | 952K | |
30M | 56.2M | 356.9M | 31.2M | 312M | 312M | 130.8M | 64.2M | 53.9M | 17.8M | -43.4M | -6.5M | 30.7M | 10.7M | 8.5M | -6.9M | 43.1M | 10.3M | 21.4M | 31.3M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
128K | -551K | -185K | -366K | -1.4M | -1.4M | 94K | 29K | -20K | 244K | -85K | 149K | -1.1M | -288K | 902K | 521K | -739K | -218K | -322K | -243K | |
22M | -82.1M | 136.3M | -102.6M | 79.5M | 79.5M | 60.7M | 18.1M | 6.6M | 2.8M | 8.5M | -8.5M | -1.6M | -896K | 1.6M | -2.5M | 13.1M | -8.2M | -7.5M | 8.9M | |
138.8M | 221M | 84.7M | 187.2M | 107.8M | 107.8M | 47.1M | 29.1M | 22.5M | 19.8M | 11.2M | 19.7M | 21.3M | 22.2M | 20.7M | 23.2M | 10.1M | 18.3M | 25.8M | 16.9M | |
160.8M | 138.8M | 221M | 84.7M | 187.2M | 187.2M | 107.8M | 47.1M | 29.1M | 22.6M | 19.8M | 11.2M | 19.7M | 21.3M | 22.2M | 20.7M | 23.2M | 10.1M | 18.3M | 25.8M | |
2.8M | -137.8M | -165.5M | -133.4M | -141.9M | -141.9M | -70.3M | -46.2M | -32.5M | -16.3M | -19.1M | -2.1M | -31.6M | -7.3M | -5.8M | 4.5M | -31.2M | -18.7M | -32.9M | -21.2M |
ATEC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | February 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 30, 2025 | September 30, 2025 | 2025 |
Continue your ATEC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.